Hepatitis C: evidence brief
Open Source Medicine Foundation · page built 16 November 2026 · trial data searched 2026-11-16 · https://research.opensourcemed.info/briefs/hepatitis-c.html
Research information, not medical advice. Prepared to support a conversation with a clinician, not to choose a treatment.
Medicines with registered trials
Scale: trials listed for each medicine on the tracker's condition page, a snapshot of ClinicalTrials.gov. A trial means it is being studied, not that it works.
- Ribavirin 8 trials
- Peginterferon alfa-2b (SCH 54031) 5 trials
- Daclatasvir (BMS-790052) 3 trials
- Danoprevir 3 trials
- Pegylated interferon alpha 2a and ribavirin 3 trials
- BI 201335 NA 120 mg capsule 2 trials
Non-drug approaches tested
Scale: trial status on ClinicalTrials.gov (completed, results posted). Status is not a result.
- Education, coaching and self-management 35 trials · 23 completed · 13 with results
- Care coordination, navigation and outreach 16 trials · 10 completed · 4 with results
- Behavioural treatment for alcohol, smoking and drug use 5 trials · 5 completed · 3 with results
- Psychotherapy, counselling and peer support 11 trials · 10 completed · 1 with results
- Cognitive behavioural and related therapies 4 trials · 3 completed · 0 with results
- Nutrition counselling and food-based products 3 trials · 3 completed · 0 with results
Natural products (RepurpOS Moderate tier)
Scale: RepurpOS evidence tier, from linked trials and literature. Product quality and dose vary.
- Silymarin
- Black Seed Oil
- Tudca
Biomarkers reported
Direction in patients compared with the stated comparison group, as reported in the cited study.
- Alpha-Fetoprotein higher · Nakao et al. 2013
- ALT higher · Woo et al. 2024
- AST higher · Al-Rawaf et al. 2024
- Cryoglobulins higher · Siagris et al. 2002
- FIB-4 Index higher · Krassenburg et al. 2023
- Gamma-Glutamyl Transferase (GGT) higher · Khadem Ansari et al. 2015
Trials recruiting
Status as recorded on ClinicalTrials.gov when searched (2026-11-16); check the registry for current status and eligibility.
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia,… NCT06159504
- Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in… NCT07040319
- Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir… NCT03855917
- Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons NCT07122219
- Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who… NCT06179498
- Project I Test: Implementing HIV Testing in Opioid Treatment Programs NCT03135886
What we don't know yet
Gaps in registered trials, from the evidence-gap map. A gap is not a recommendation.
- Among 21 trials of supplements and nutraceuticals found, none measured symptom severity and disease activity 12 trials of other approaches did
- Among 35 trials of cognitive training and education found, none measured quality of life 5 trials of other approaches did
- Among 16 trials of care delivery and health services found, none measured quality of life 5 trials of other approaches did
- Supplements and nutraceuticals: inflammation and other biomarkers 13 trials, no results posted yet
- Mind-body and psychological approaches: mood, anxiety and wellbeing 4 trials, no results posted yet